Search

Aleni Flores-Nate

from Union City, CA
Get Report
Related to:
Aleni F Nate, 68Gerard P Nate, 66Melody P Nate, 52Jordanee P Nate, 50Lolita P Nate, 86Glenn Nate, 37
Connected to:
Aaron S Flores, 51Abel Flores, 59Adan Flores, 44Addiel Flores, 42Adelita Flores, 48Adina Flores, 48Adriel Flores, 51Agustin Flores, 51Aimee L Flores, 55Alex Flores, 65

Aleni Flores-Nate Phones & Addresses

  • 4605 Dinuba St, Union City, CA 94587

Publications

Us Patents

Stable Lyophilized Pharmaceutical Formulation Of Igg Antibodies

View page
US Patent:
8298530, Oct 30, 2012
Filed:
Aug 12, 2009
Appl. No.:
12/540320
Inventors:
Elizabet A. Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US
Assignee:
Facet Biotech Corporation - Redwood City CA
International Classification:
A61K 39/395
US Classification:
4241301, 4241411, 4241441
Abstract:
This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e. g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5. 5 to about 6. 5, about 0. 005%-0. 03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

Stable Lyophilized Pharmaceutical Formulation Of Igg Antibodies

View page
US Patent:
20030113316, Jun 19, 2003
Filed:
Jul 25, 2002
Appl. No.:
10/206469
Inventors:
Elizabet Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US
International Classification:
A61K039/395
US Classification:
424/130100
Abstract:
This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

Stable Lyophilized Pharmaceutical Formulation Of Igg Antibodies

View page
US Patent:
20060029599, Feb 9, 2006
Filed:
Oct 14, 2005
Appl. No.:
11/250835
Inventors:
Elizabet Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US
International Classification:
A61K 39/395
US Classification:
424133100
Abstract:
This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.
Control profile
Aleni Flores-Nate from Union City, CA Get Report